CV Lattes
ResearcherID
ORCID
Secretaria da Saúde (São Paulo - Estado). Instituto Butantan (Institutional affiliation for the last research proposal) Birthplace: Brazil
Graduate in Biological Sciences at Universidade de São Paulo (1992), and ph.d. in Genetics at Universidade de São Paulo (1997). Has experience in vaccine development, acting on the following subjects: Streptococcus pneumoniae and adjuvants. (Source: Lattes Curriculum)
Streptococcus pneumoniae is an important human pathogen, causing diseases such as otitis media, sinusitis, pneumonia, bacteremia and meningitis. The polysaccharide conjugate vaccines are based on the induction of antibodies against the capsular polysaccharide and are very efficient in preventing invasive disease in children. Substitution by non-vaccine serotypes in colonization of the nas…
Streptococcus pneumoniae is an important human pathogen, causing diseases such as otitis media, sinusitis, pneumonia, bacteremia and meningitis. Polysaccharide conjugate vaccines (PCV) are based on the induction of antibodies against capsular polysaccharides and they are very efficient against invasive pneumococcal infections. The widespread use of PCVs has also led to an increase in colo…
Streptococcus pneumoniae is an important human pathogen, causing severe diseases such as meningitis, pneumonia, bacteremia and sepsis. The currently available vaccines are based on the response to the capsular polysaccharide and they have some shortcomings, such as high production cost and coverage restricted to the serotypes included in the formulation. The use of the 7-valent conjugate …
The development of a vaccine based on "common pneumococcal proteins" offers the potential for serotype-independent protection overcoming the problem of serotype replacement that emerged after pneumococcal conjugate vaccine widespread use. Researchers at the Butantan Institute have been evaluating the pneumococcal antigens PspA and PspC as vaccine candidates. Although these proteins are va…
(Only some records are available in English at this moment)
Streptococcus pneumoniae, or pneumococcus, is a component of the human microbiota, but in some cases it can cause diseases such as Sinusitis, Otitis Media, Pneumonia, Sepsis and Meningitis. Vaccination is the most effective strategy to control pneumococcal infections. The first generation pneumococcal vaccines are composed by free capsular polysaccharides (PS), inducing temporary protecti…
Streptococcus pneumoniae is an important human pathogen, causing severe diseases such as pneumonia, bacteremia, sepsis and meningitis. The currently available vaccines are based on the response against the capsular polysaccharide, but they have some shortcomings such as high cost and restricted serotype coverage. The development of new vaccines against pneumococcal infections thus remains…
Streptococcus pneumoniae is an important human pathogen, causing many severe diseases such as meningitis, pneumonia, bacteremia and sepsis. The vaccines currently available are based on the induction of antibodies against the capsular polysaccharide, but they present some disadvantages, such as high cost and coverage restricted to serotypes included in the formulations. The use of the 7-v…
Streptococcus pneumoniae is an important human pathogen, causing severe diseases such as meningitis, pneumonia, bacteremia and sepsis. The currently avaliable vaccines induce anti-capsular polysaccharide antibodies and have some disadvantages, such as limited serotype coverage and high production costs. The widespread use of the 7-valent conjugate polysaccharide vaccine led to a drastic r…
(Only some records are available in English at this moment)
Streptococcus pneumoniae, or pneumococcus, is a component of human microbiota, but in some cases it can cause serious diseases. Vaccines are the most important way to control pneumococcal infections and there are currently two licensed vaccines based on capsular polysaccharides (PS). The pneumococcal conjugate vaccines (PCVs) led to an impressive decrease in the cases of invasive pneumoco…
| 1 / 1 | Ongoing research grants |
| 11 / 9 | Completed research grants |
| 1 / 1 | Ongoing scholarships in Brazil |
| 11 / 6 | Completed scholarships in Brazil |
| 1 / 1 | Completed scholarships abroad |
| 25 / 18 | All research grants and scholarships |
| Associated processes | |
(References retrieved automatically from Web of Science and SciELO through information on FAPESP grants and their corresponding numbers as mentioned in the publications by the authors)
| Publications | 6 |
| Citations | 24 |
| Cit./Article | 4.0 |
| Data from Web of Science | |
COLICHIO, GABRIELA B. C.; OLIVEIRA, GIULIANA S.; RODRIGUES, TASSON C.; OLIVEIRA, MARIA LEONOR S.; MIYAJI, ELIANE N.. Efficacy of a Protein Vaccine and a Conjugate Vaccine Against Co-Colonization with Vaccine-Type and Non-Vaccine Type Pneumococci in Mice. PATHOGENS, v. 9, n. 4, APR 2020. Web of Science Citations: 0. (16/09427-5)
ARAUJO, ADRIANO P.; COLICHIO, GABRIELA B. C.; OLIVEIRA, MARIA LEONOR S.; GERMAN, ESTHER; NIKOLAOU, ELISSAVET; CHEN, TAO; ADLER, HUGH; FERREIRA, DANIELA M.; MIYAJI, ELIANE N.. Serum levels of anti-PspA and anti-PspC IgG decrease with age and do not correlate with susceptibility to experimental human pneumococcal colonization. PLoS One, v. 16, n. 2, FEB 12 2021. Web of Science Citations: 0. (18/25165-6)
GENSCHMER, KRISTOPHER R.; VADESILHO, CINTIA F. M.; MCDANIEL, LARRY S.; PARK, SANG-SANG; HALE, YVETTE; MIYAJI, ELIANE N.; BRILES, DAVID E.. The Modified Surface Killing Assay Distinguishes between Protective and Nonprotective Antibodies to PspA. MSPHERE, v. 4, n. 6, NOV-DEC 2019. Web of Science Citations: 0. (11/13671-5)
RODRIGUES, TASSON C.; OLIVEIRA, MARIA LEONOR S.; SOARES-SCHANOSKI, ALESSANDRA; CHAVEZ-RICO, STEFANNI L.; FIGUEIREDO, DOUGLAS B.; GONCALVES, VIVIANE M.; FERREIRA, DANIELA M.; KUNDA, NITESH K.; SALEEM, IMRAN Y.; MIYAJI, ELIANE N.. Mucosal immunization with PspA (Pneumococcal surface protein A)-adsorbed nanoparticles targeting the lungs for protection against pneumococcal infection. PLoS One, v. 13, n. 1, JAN 23 2018. Web of Science Citations: 11. (15/06255-6, 14/25436-9)
TOSTES, RAFAELLA O.; RODRIGUES, TASSON C.; DA SILVA, JOSEFA B.; SCHANOSKI, ALESSANDRA S.; OLIVEIRA, MARIA LEONOR S.; MIYAJI, ELIANE N.. Protection Elicited by Nasal Immunization with Recombinant Pneumococcal Surface Protein A (rPspA) Adjuvanted with Whole-Cell Pertussis Vaccine (wP) against Co-Colonization of Mice with Streptococcus pneumoniae. PLoS One, v. 12, n. 1, JAN 19 2017. Web of Science Citations: 2. (13/17699-7)
VADESILHO, CINTIA F. M.; FERREIRA, DANIELA M.; GORDON, STEPHEN B.; BRILES, DAVID E.; MORENO, ADRIANA T.; OLIVEIRA, MARIA LEONOR S.; HO, PAULO L.; MIYAJI, ELIANE N.. Mapping of Epitopes Recognized by Antibodies Induced by Immunization of Mice with PspA and PspC. Clinical and Vaccine Immunology, v. 21, n. 7, p. 940-948, JUL 2014. Web of Science Citations: 11. (12/50816-4, 11/13671-5)
(References retrieved automatically from State of São Paulo Research Institutions)
FERREIRA, Daniela Mulari. Vacinas de DNA contra Streptococcus pneumoniae baseadas em PspA (Pneumococcal surface protein A) e PspC (Pneumococcal surface protein C). 154 f. Tese (Doutorado) - Instituto de Ciências Biomédicas. Universidade de São Paulo (USP). São Paulo. (05/58549-1)